Beiyun Wang1, Yuan Zhong1, Hong Yan1, Liang Cui1. 1. Department of Geriatrics, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University Shanghai 200233, China.
Abstract
OBJECTIVE: To evaluate the relationship between homocysteine and cognitive function of Alzheimer's disease (AD) patients and vascular dementia (VD) patients. METHODS: By Cochrane system evaluation we retrieved relevant publications from MEDLINE, Embase, OVID, controlled clinical trial database of the Cochrane library and others. Two evaluators jointly assessed the research quality of the retrieved publications and carried out meta-analysis on the homogeneous study. RESULTS: MMSE score in the AD group was lower than that in normal control group (MD = -11.98, 95% CI (-13.30, -10.65)), and the homocysteine content was higher than that in the normal control group (MD = 2.72, 95% CI (1.79, 3.64)), with a statistical difference between the two groups (P < 0.05). The homocysteine content in the AD group was higher than that in the VD group (MD = -4.76, 95% CI (-7.59, -1.93), P < 0.05). CONCLUSIONS: MSE score and homocysteine content can be used as useful indicators to distinguish AD and normal subjects; homocysteine content can be used as an indicator to differentiate AD from VD. Clinically, more randomized controlled trials are needed to test and verify the relationship in cognitive function between homocysteine and AD and VD.
OBJECTIVE: To evaluate the relationship between homocysteine and cognitive function of Alzheimer's disease (AD) patients and vascular dementia (VD) patients. METHODS: By Cochrane system evaluation we retrieved relevant publications from MEDLINE, Embase, OVID, controlled clinical trial database of the Cochrane library and others. Two evaluators jointly assessed the research quality of the retrieved publications and carried out meta-analysis on the homogeneous study. RESULTS: MMSE score in the AD group was lower than that in normal control group (MD = -11.98, 95% CI (-13.30, -10.65)), and the homocysteine content was higher than that in the normal control group (MD = 2.72, 95% CI (1.79, 3.64)), with a statistical difference between the two groups (P < 0.05). The homocysteine content in the AD group was higher than that in the VD group (MD = -4.76, 95% CI (-7.59, -1.93), P < 0.05). CONCLUSIONS: MSE score and homocysteine content can be used as useful indicators to distinguish AD and normal subjects; homocysteine content can be used as an indicator to differentiate AD from VD. Clinically, more randomized controlled trials are needed to test and verify the relationship in cognitive function between homocysteine and AD and VD.
Entities:
Keywords:
Alzheimer’s disease; cognitive function; elderly people; homocysteine; meta analysis
Authors: Cristiane Matté; Emilene B S Scherer; Francieli M Stefanello; Alethéa G Barschak; Carmen R Vargas; Carlos A Netto; Angela T S Wyse Journal: Int J Dev Neurosci Date: 2007-10-07 Impact factor: 2.457
Authors: Sungeun Kim; Kwangsik Nho; Vijay K Ramanan; Dongbing Lai; Tatiana M Foroud; Katie Lane; Jill R Murrell; Sujuan Gao; Kathleen S Hall; Frederick W Unverzagt; Olusegun Baiyewu; Adesola Ogunniyi; Oye Gureje; Mitchel A Kling; P Murali Doraiswamy; Rima Kaddurah-Daouk; Hugh C Hendrie; Andrew J Saykin Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472